ARMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the investor's beginner level, long-term strategy, and available capital, ARMP is not a strong buy at the moment. While the stock shows some technical bullishness and a positive analyst rating, the lack of significant trading trends, weak financial performance, and absence of recent news or catalysts suggest it is better to hold off on investing in this stock right now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.116). RSI is neutral at 72.29, and the stock is trading near its resistance level (R1: 8.31). However, the stock's candlestick pattern suggests limited short-term upside potential, with a 60% chance of a -0.14% change in the next day and -2.32% in the next month.
Analyst Debanjana Chatterjee initiated coverage with a Buy rating and a $15 price target, citing Armata's proprietary phage platform and in-house manufacturing capabilities. The stock has bullish technical indicators, and gross margin remains strong at 100%.
Congress trading data is unavailable, and options data indicates low trading volume and a high put-call ratio, suggesting bearish sentiment.
In Q3 2025, revenue dropped significantly by 61.02% YoY to $1,159,000. Net income improved but remains negative at -$26,675,000, up 386.68% YoY. EPS also improved to -0.74, up 393.33% YoY. Gross margin stayed at 100%, showing operational efficiency despite declining revenue.
Analyst Debanjana Chatterjee from JonesResearch initiated coverage with a Buy rating and a $15 price target, highlighting Armata's unique phage platform and manufacturing capabilities. However, no other recent analyst updates or price target changes are available.
